16 Sep How Novel Cancer Therapies Affect Billing & Reimbursement
Cancer care is going through big changes due to advancement in healthcare research. For many years, the main treatments were surgery, chemotherapy, and radiation. These are still important, but now new options like immunotherapy and targeted therapy are improving results for patients. But with these new treatments also come new challenges.
They have completely changed how cancer clinics handle billing and payments. For oncology providers, keeping up with these changes is important to stay financially secure. This article looks at new cancer treatments, how they affect billing, the challenges clinics face, and how trusted oncology billing services providers help providers handle these issues.
Overview of Novel Cancer Therapies
To understand how billing is changing, it’s important to first look at the new treatments that are reshaping cancer care.
1.Immunotherapy
Immunotherapy helps the body’s own immune system detect and fight cancer cells. The most common types include:
- Checkpoint inhibitors (e.g., pembrolizumab/Keytruda, nivolumab/Opdivo) which release “brakes” on T-cells so they can attack tumors.
- CAR-T cell therapies (e.g., Kymriah, Yescarta) that genetically engineer a patient’s immune cells to recognize and eliminate cancer.
- Cytokine therapies and monoclonal antibodies that stimulate or direct immune responses against tumors.
Unlike regular chemotherapy, which attacks all fast-growing cells, immunotherapy focuses more directly on cancer cells. It can also give longer-lasting results, and for some cancers, it has even made a cure possible where none was before.
2.Targeted Therapies
Targeted therapies focus on the specific changes or molecules that cause cancer to grow. These treatments identify genetic mutations or proteins that fuel tumor growth and block them directly. Examples include:
- Tyrosine kinase inhibitors (TKIs): drugs that interfere with signaling pathways needed for cancer growth (e.g., imatinib for chronic myeloid leukemia).
- Monoclonal antibodies: engineered proteins that bind to specific cancer targets, sometimes linked with toxins to deliver a lethal blow to tumor cells.
- Anti-angiogenic agents: drugs that prevent tumors from forming new blood vessels.
Impact on Billing & Reimbursement
Immunotherapies and targeted therapies are leading the way in cancer treatment. But these new options are very expensive, and that makes billing and insurance payments more challenging. Here are some of the key impacts of these new therapies on billing and reimbursements:
1. Complex Coding and Documentation
Billing for novel therapies needs extreme precision unlike traditional chemotherapy. Each therapy may have a unique HCPCS or CPT code, and correct documentation of drug name, dosage, route of administration, and even sequential dosing is essential. For instance, CAR-T therapies and checkpoint inhibitors often carry distinct codes and modifiers that must be applied accurately. Any missing modifier or miscoding leads to claim denials or payment delays.
- Stricter Payer Policies and Prior Authorization
Because these treatments are so costly, insurance companies review them very carefully. They often ask for:
- Prior authorization with supporting clinical evidence.
- Documentation of biomarker testing or genetic mutations.
- Proof that other therapies have failed before approving immunotherapy or targeted therapy.
- Rising Cost Structures
The financial risks are also immense in billing for these novel cancer therapies. A single CAR-T infusion can cost around $370,000, while a year of checkpoint inhibitor therapy may cost nearly $190,000. Clinics usually pay for these drugs first under buy-and-bill, which means they take on the risk if insurance refuses to pay later.
Key Challenges for Providers
Dealing with new cancer therapies is not just about medical care, it also brings financial and administrative hurdles. Providers face several key challenges:
- Administrative Overload: Staff have to handle prior authorizations, appeals, coding updates, and compliance reviews, which often takes away valuable time that could be spent on patient care.
- Cash Flow Risks: Denied or delayed claims can tie up hundreds of thousands of dollars that puts practice financial stability at risk.
- Regulatory Complexity: Rules from CMS and the National Correct Coding Initiative (NCCI) change often, so providers must stay alert to avoid compliance problems.
- Revenue Leakage: Even small errors in coding high-value claims result in significant lost revenue, which many smaller practices cannot tolerate.
These challenges highlight why many oncology providers seek expert partners to streamline billing and protect financial health.
How Oncology Billing Companies Help
Specialized oncology billing companies bring the expertise and tools needed to manage the financial complexities of novel therapies. One leading example is Transcure, a revenue cycle management partner that has developed tailored solutions for oncology practices.
Transcure’s Role in Supporting Oncology Practices
- Oncology-Specific Expertise: Transcure employs billers and coders trained in oncology-specific codes, payer rules, and compliance standards. Their teams ensure that immunotherapy and targeted therapy claims are submitted accurately the first time.
- Denial Management and Claim Scrubbing: Through advanced technology and automated claim scrubbing, Transcure minimizes denials. The company reports achieving a 98% first-pass clean claims rate and helping practices reduce average accounts receivable days to just 24, compared to an industry average of 40.
- Revenue Optimization: By reducing administrative workload and ensuring compliance, Transcure enables practices to focus on patient care while maintaining financial stability. Their data-driven approach has improved revenue capture, with clients reporting measurable increases in collections.
- Scalability and Support: Whether a small oncology practice or a multi-location cancer center, Transcure offers customizable solutions, from eligibility verification to 24/7 claim support. This flexibility allows practices to keep pace with changing payer policies and the growing volume of high-cost therapies.
Conclusion
In conclusion, novel cancer therapies like immunotherapy and targeted therapy are transforming patient outcomes but also making billing and reimbursement more complex. High costs, strict payer rules, and evolving regulations create major challenges for providers. Partnering with expert oncology billing companies helps practices minimize risks, optimize revenue, and stay financially secure while focusing on patient care.
———
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. Products are not warranted or endorsed.
Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on September 16, 2025 by Marie Benz MD FAAD